{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:53:40Z","timestamp":1791003220614,"version":"4.1.0"},"reference-count":69,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Urothelial cancer is a lethal malignancy characterized by a wide diffusion in Western countries due to a larger exposure to known risk factors, such as aromatic amines, tobacco smoke and benzene [...]<\/jats:p>","DOI":"10.3390\/cells11101614","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T10:19:46Z","timestamp":1652264386000},"page":"1614","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?"],"prefix":"10.3390","volume":"11","author":[{"given":"Marco","family":"Audisio","sequence":"first","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2877-2518","authenticated-orcid":false,"given":"Consuelo","family":"Buttigliero","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-7888","authenticated-orcid":false,"given":"Fabio","family":"Turco","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-9166","authenticated-orcid":false,"given":"Marco Donatello","family":"Delcuratolo","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pisano","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Parlagreco","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario Francesco","family":"Di Stefano","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Di Prima","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Crespi","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Farinea","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Cani","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cardinal Massaia Hospital, 14100 Asti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_2","first-page":"1","article-title":"Metastatic Urothelial Cancer: A rapidly changing treatment landscape","volume":"13","author":"Carlos","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Audisio, A., Buttigliero, C., Delcuratolo, M.D., Parlagreco, E., Audisio, M., Ungaro, A., Di Stefano, R.F., Di Prima, L., Turco, F., and Tucci, M. (2022). New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond. Cells, 11.","DOI":"10.3390\/cells11030357"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant Chemotherapy Plus Cystectomy Compared With Cystectomy Alone for Locally Advanced Bladder Cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1200\/JCO.1997.15.7.2564","article-title":"Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study","volume":"15","author":"Saxman","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study","volume":"17","author":"Maase","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1016\/j.annonc.2021.08.095","article-title":"Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)","volume":"32","author":"Rosenberg","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","article-title":"Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Szklener, K., Chmiel, P., Michalski, A., and Ma\u0144dziuk, S. (2022). New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors. Cancers, 14.","DOI":"10.3390\/cancers14061416"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2217\/imt-2021-0042","article-title":"Urothelial carcinoma in the era of immune checkpoint inhibitors","volume":"13","author":"Khalife","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41585-020-00394-5","article-title":"The biology and rationale of targeting nectin-4 in urothelial carcinoma","volume":"18","author":"Heath","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors abstract","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.urology.2014.10.020","article-title":"Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma","volume":"85","author":"Faraj","year":"2015","journal-title":"Urology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J. Urol."},{"key":"ref_22","first-page":"121","article-title":"Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer","volume":"39","author":"Sfakianos","year":"2021","journal-title":"Urol. Oncol. Semin Orig. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5618174","DOI":"10.1155\/2017\/5618174","article-title":"Immunotherapy for patients with advanced urothelial cancer: Current evidence and future perspectives","volume":"2017","author":"Zichi","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Yang, H.Y., Wu, C.Y., Chen, J.J., and Lee, T.H. (2020). Treatment strategies and metabolic pathway regulation in urothelial cell carcinoma: A comprehensive review. Int. J. Mol. Sci., 21.","DOI":"10.20944\/preprints202010.0338.v1"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13174411","article-title":"Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives","volume":"13","author":"Roviello","year":"2021","journal-title":"Cancers"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): A randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): A randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): A multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1711","DOI":"10.1634\/theoncologist.2020-0334","article-title":"Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer","volume":"25","author":"Garje","year":"2020","journal-title":"Oncologist"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/jclinpath-2020-207115","article-title":"Fibroblast growth factor receptor (FGFR) gene: Pathogenesis and treatment implications in urothelial carcinoma of the bladder","volume":"74","author":"Cheng","year":"2021","journal-title":"J. Clin. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: Genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","article-title":"Evaluation of BGJ398, a Fibroblast growth factor receptor 1-3 kinase inhibitor, in patientswith advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: Results of a global phase I, dose-escalation and dose-expansion stud","volume":"35","author":"Nogova","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","article-title":"Efficacy of BGJ398, a fibroblast growth factor receptor 1\u20133 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations","volume":"8","author":"Pal","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1200\/JCO.19.02630","article-title":"Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: Results from the NCI-MATCH Trial. (EAY131) subprotocol W","volume":"38","author":"Chae","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: A phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1200\/JCO.2020.38.6_suppl.489","article-title":"FORT-1: Phase II\/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1\/3 mRNA expression","volume":"30","author":"Quinn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"27006","DOI":"10.1074\/jbc.M203228200","article-title":"Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin4 bind to the predicted C-C\u2032-C\u2033-D \u03b2-strands of the nectin1 V domain","volume":"277","author":"Fabre","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Satpayev","year":"2016","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.biocel.2017.06.007","article-title":"Nectin-4 is a breast cancer stem cell marker that induces WNT\/\u03b2-catenin signaling via Pi3k\/Akt axis","volume":"89","author":"Siddharth","year":"2017","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/cgt.2008.15","article-title":"The ERBB3 receptor in cancer and cancer gene therapy","volume":"15","author":"Sithanandam","year":"2008","journal-title":"Cancer Gene Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-Drug Conjugate-Based Therapeutics: State of the Science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Ungaro, A., Tucci, M., Audisio, A., Di Prima, L., Pisano, C., Turco, F., Delcuratolo, M.D., Di Maio, M., Scagliotti, G.V., and Buttigliero, C. (2022). Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. Cells, 11.","DOI":"10.3390\/cells11050803"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A phase I study of single-agent enfortumab vedotin in patients with nectin-4\u2013positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s10637-019-00844-x","article-title":"A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Takahashi","year":"2020","journal-title":"Invest. New Drugs."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): A multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2021.39.15_suppl.4528","article-title":"Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la\/mUC)","volume":"39","author":"Friedlander","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fonc.2020.568279","article-title":"Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer","volume":"10","author":"Zucali","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 507, 315\u2013322.","DOI":"10.1038\/nature12965"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/10\/1614\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:09:30Z","timestamp":1760137770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/10\/1614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":69,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["cells11101614"],"URL":"https:\/\/doi.org\/10.3390\/cells11101614","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]}}}